Is GLP-1 Naturally Occurring? Understanding Your Genetic Response

Last reviewed: May 24, 2026

Last updated: May 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 (glucagon-like peptide-1) is naturally occurring—your pancreas and intestines produce it daily to regulate blood sugar, suppress hunger, and slow gastric emptying. Understanding this endogenous hormone and your body's unique receptor sensitivity can inform whether exogenous GLP-1 therapy aligns with your metabolic profile.

Beyond knowing GLP-1 exists naturally, what matters clinically is how your individual genetics and biomarkers influence your response to GLP-1 medications. PlexusDx combines genetic predisposition testing with clinical guidance to support a more personalized treatment conversation with your healthcare provider.

What GLP-1 Is and How Your Body Produces It Naturally

GLP-1 is a 30-amino acid peptide hormone secreted by intestinal L-cells in response to nutrient ingestion, particularly glucose and amino acids. It binds to GLP-1 receptors in the pancreas, brain, and gut to regulate insulin secretion, appetite signaling, and gastric motility.

Your body tightly controls GLP-1 levels—rising after meals and declining during fasting. This natural rhythm supports postprandial glucose stability and satiety. However, in conditions like type 2 diabetes, endogenous GLP-1 secretion may be impaired, reducing its glucose-lowering and weight management effects.

Genetic Variation in GLP-1 Receptor Sensitivity and Treatment Response

Not all individuals respond identically to GLP-1 therapies. Genetic variants in the GLP1R gene (such as rs6923761) influence receptor function, signaling efficiency, and potentially medication efficacy. Understanding your genetic predisposition can help providers anticipate whether you may be a robust responder or require dose optimization.

Genetic Factor	Key Information
GLP1R rs6923761 variant	Influences GLP-1 receptor binding affinity and cellular signaling; may correlate with variable treatment response
GIPR rs1800437 variant	Affects GLP-dependent insulinotropic peptide (GIP) receptor function; relevant when considering dual GLP-1/GIP therapies
FTO rs9939609 variant	Associated with baseline obesity risk and appetite regulation; provides metabolic context for treatment selection
MC4R rs17782313 variant	Influences melanocortin pathway appetite signaling; may indicate whether appetite-suppression mechanisms will be prominent

Why Biomarkers and Metabolic Testing Matter Before Starting GLP-1 Therapy

Before initiating GLP-1 treatment, assessing baseline fasting glucose, HbA1c, lipid panels, and inflammatory markers provides essential context. These biomarkers reveal whether glucose dysregulation, metabolic syndrome, or inflammation are primary drivers of your weight and metabolic health, informing whether GLP-1 aligns with your clinical picture.

Combined with genetic predisposition data, biomarkers help providers distinguish responders from non-responders earlier. Someone with poor GLP1R receptor function may require alternative or adjunctive strategies, while a patient with robust genetic predisposition may benefit from earlier, more aggressive dosing protocols under clinical supervision.

Safety Considerations and Who Should Evaluate GLP-1 Therapy

GLP-1 therapies are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid cancer, MEN 2 syndrome, severe gastroparesis, and active pancreatitis. Pregnancy, breastfeeding, and certain psychiatric conditions also require careful provider evaluation before initiation.

Genetic testing and biomarker assessment should complement, not replace, comprehensive clinical evaluation. A qualified healthcare provider will review your medical history, current medications, family risk factors, and metabolic labs to determine whether GLP-1 therapy is safe and likely to be effective for your situation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions across key GLP-1 and peptide pathway genes—GLP1R, GIPR, FTO, and MC4R—helping you and your provider understand your individual genetic context for medication response. This information may help provide context for treatment selection and dosing strategy discussions.

The genetic test does not predict exact medication response or guarantee outcomes; rather, it identifies whether your genetic profile aligns with phenotypes associated with robust GLP-1 signaling, strong appetite suppression, or metabolic responsiveness. Results should be interpreted with a qualified healthcare provider to inform personalized treatment planning.

When you combine genetic predisposition insights with baseline biomarkers and clinical history, you create a more complete picture for your provider. This evidence-based approach can support a more informed conversation about whether compounded GLP-1 options (such as compounded semaglutide or tirzepatide) align with your metabolic profile and treatment goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.